Your request has been received.
We will send you more information as it becomes available.
days to go: ASP+6% CMS reimbursement for proven non-opioids used in all outpatient surgical settings is coming January 1, 2025.
For adults, a maximum dose of 266 mg (20 mL) is recommended, based on:
For pediatric patients aged 6 to less than 17 years, dosing is weight based: 4 mg/kg (up to a maximum of 266 mg)
The first and only FDA-approved long-lasting local analgesic for ages 6 and above.1 Demonstrated in PLAY, a clinical trial centered uniquely on safety in children.2 Pediatric patients in the EXPAREL study were defined as 6 to <17 years of age.
A multicenter, open-label, phase 3 trial with 2 parts including pediatric patients 6 to <17 years of age
Age Group 1 12 to <17 years old Spine surgery
Local infiltration
Blood samples collected from 0.25 to 60 hours after treatment
Age Group 2 6 to <12 years old Spine or cardiac surgery
Local infiltration
Spine
Cardiac
Blood samples collected 0.25 to 60 hours after treatment for spine surgery, 0.25 to 72 hours after treatment for cardiac surgery
Baseline characteristics were generally comparable among groups.
*Maximum total dose of 266 mg.
†Maximum total dose of 175 mg.
EXPAREL was well tolerated for all age groups, with TEAEs being mild or moderate and no discontinuations3
Patients aged 6 to <17 years old | Patients aged 6 to <12 years old | |
Spine surgery EXPAREL 4 mg/kg; n=36 (%) | Cardiac surgery EXPAREL 4 mg/kg; n=29 (%) | |
Vision blurred | 7 (19.4) | 1 (3.4) |
Constipation | 9 (25) | 4 (13.8) |
Nausea | 11 (30.6) | 2 (6.9) |
Hypoesthesia oral | 4 (11.1) | 0 |
Vomiting | 10 (27.8) | 4 (13.8) |
Anemia postoperative | 5 (13.9) | 0 |
Muscle spasms | 4 (11.1) | 0 |
Hypotension | 4 (11.1) | 0 |
TEAE, treatment-emergent adverse event.
There is not enough evidence to determine if the numbers associated with spine surgery in patients aged 12 to <17 years old are indicative of differences in the surgery types.
The PK profile of EXPAREL in pediatric patients was:
Cmax, maximum concentration.
The bupivacaine HCI data is for reference purposes only and does not reflect an active comparator in the study.
The PK profile of EXPAREL in pediatric patients was:
Cmax, maximum concentration.
The bupivacaine HCI data is for reference purposes only and does not reflect an active comparator in the study.
The risks and complications of adult-based pain management approaches may be magnified in children.5 Opioids, short-acting local anesthetics, and delivery devices are the mainstay despite safety implications and limited studies in children.5
50% of children report moderate to severe pain in the hospital after surgery6
~20% of children report chronic pain 12 months after surgery6
Opioids can be attributed to 50% of postsurgical respiratory failure events in children and may also hinder recovery, extend hospital stay, and negatively impact both patient and parent experience.7-9
Opioids5
Device-based platforms (ie, pumps and catheters)
Medical societies recommend non-opioid analgesics and a multimodal approach to pain management for pediatric patients13
American Society of Anesthesiologists
Task Force on Acute Pain Management14
Analgesic therapy [for pediatric patients] should depend upon age, weight, and comorbidity, and unless contraindicated should involve a multimodal approach.
Society for Pediatric Anesthesia
Guidelines from the Society of Pediatric Anesthesia15
…clinicians should use all methods possible to minimize the use of opioids… Use of nonopioid analgesia is encouraged including regional analgesia techniques…
JAMA
Expert panel* guidelines that include the American College of Surgeons Education Committee16
…health care professionals caring for children who require surgery must recognize the risks of opioid misuse associated with prescription opioids, [and] nonopioid analgesic use should be optimized in the perioperative period…
*This guideline was developed by the American Pediatric Surgical Association Outcomes and Evidence-Based Practice Committee, in addition to a geographically diverse multidisciplinary team composed of leaders in pediatric opioid stewardship from academic and community hospitals and representatives from the American College of Surgeons (ACS) Education Committee, the American Academy of Pediatrics Section on Surgery, pediatric anesthesia, pediatric nursing, general surgery residency, pediatric surgery physician assistants, and addiction science.17
See how your peers are using EXPAREL for optimal pain coverage
ASP, average sales price; CMS, Centers for Medicare and Medicaid Services.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.
Please refer to full Prescribing Information.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration
This website uses cookies to give you a better browsing experience. By clicking the "Allow all cookies" button, you agree to our use of cookies. For additional information, see our Cookie Notice.